Acsel Health, an OPEN Health Company
We have broad expertise in bringing therapies to the patients who need them. By working together to remove barriers, we can we can improve outcomes for patients by helping get life-saving treatments to market faster.
OPEN Health’s rich heritage in oncology spans 20+ years
>50% of our staff have valuable experience in this field
Through thousands of projects delivered over many years, we have unparalleled connections in oncology
We maintain our expertise by regularly interacting with thought leaders in the field, attending all key conferences and symposia, and staying abreast of the literature.
We work to develop optimal solutions for our clients that positively impact science, medicine, and patients’ lives.
Understand the clinical and emotional journey of HL patients, caregivers and HCPs from pre-diagnosis to treatment maintenance in three different markets
Leverage this new knowledge to achieve competitive advantage by developing differentiated tools and services to support patients, caregivers and HCPs
The HL patient journeys were used as a strategic business planning tool by the sponsor
The insights gained enabled our client to identify the key strategic leverage points along the journey and develop highly differentiated tools and services for HCPs, patients and caregivers in HL
The final deliverable encompasses a fully interactive PDF map of the HL journey, reflecting multiple user perspectives
The data also differentiates the duality of experience of HL, highlighting the clinical and emotional dissonance between treatment stakeholders
In-depth analysis of key points within the journey provides further insights for the development of strategic solutions that are specifically tailored to the stakeholder and market needs at that specific stage of the HL journey
This article explores recent developments in cancer diagnosis and treatment, including the integration of genomics, bioinformatics, and digital tools, in addition to discussing new vaccines, new treatments, and treatment resistance.
This article highlights the need for innovative methods in oncology modeling to demonstrate the value of new cancer treatments. It discusses new, flexible modeling approaches that can provide a more accurate estimate of the value of new drugs than current modeling approaches allow.
To learn more about our work in oncology and discuss what we could do for you, please get in touch.